Screener
Ocular Therapeutix OCUL Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055256
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Other liabilities: | ||
| Operating lease liabilities, net of current portion | 4,230 | 2,815 |
| Derivative liability | 12,071 | 13,903 |
| Deferred revenue | 14,000 | 14,000 |
| Notes payable, net | 72,062 | 71,336 |
| Other non-current liabilities | 909 | 887 |
| Total liabilities | 150,955 | 153,747 |
| Commitments and contingencies (Note 14) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Ocular Therapeutix's contract liabilities?
- Ocular Therapeutix (OCUL) reported contract liabilities of $14M in Q1 2026.
- How has Ocular Therapeutix's contract liabilities changed year-over-year?
- Ocular Therapeutix's contract liabilities decreased by 0.0% year-over-year, from $14M to $14M.
- What is the long-term trend for Ocular Therapeutix's contract liabilities?
- Over 5 years (2020 to 2025), Ocular Therapeutix's contract liabilities has grown at a 3.1% compound annual growth rate (CAGR), from $12M to $14M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about Ocular Therapeutix's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude